CoChat

TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML

Open access
Vadakekolathu, Jayakumar, Lai, Catherine, Reeder, Stephen, Church, Sarah E., Hood, Tressa, Lourdusamy, Anbarasu, Rettig, Michael P., Aldoss, Ibrahim, Advani, Anjali S., Godwin, John, Wieduwilt, Matthew J., Arellano, Martha, Muth, John, Yau, Tung On, Ravandi, Farhad, Sweet, Kendra, Altmann, Heidi, Foulds, Gemma A., Stölzel, Friedrich, Middeke, Jan Moritz, Ciciarello, Marilena, Curti, Antonio, Valk, Peter J. M., Löwenberg, Bob, Gojo, Ivana, Bornhäuser, Martin, DiPersio, John F., Davidson-Moncada, Jan K., Rutella, Sergio · 2020 · Blood Advances
Cited by 154

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

Somatic TP53 mutations and 17p deletions with genomic loss of TP53 occur in 37% to 46% of acute myeloid leukemia (AML) with adverse-risk cytogenetics and correlate with primary induction failure, high risk of relapse, and dismal prognosis. Herein, we aimed to characterize the immune landscape of TP53-mutated AML and determine whether TP53 abnormalities identify a patient subgroup that may benefit from immunotherapy with flotetuzumab, an investigational CD123 × CD3 bispecific dual-affinity retargeting antibody (DART) molecule. The NanoString PanCancer IO360 assay was used to profile 64 diagnostic bone marrow (BM) samples from patients with TP53-mutated (n = 42) and TP53-wild-type (TP53-WT) AML (n = 22) and 45 BM samples from patients who received flotetuzumab for relapsed/refractory (R/R) AML (15 cases with TP53 mutations and/or 17p deletion). The comparison between TP53-mutated and TP53-WT primary BM samples showed higher expression of IFNG, FOXP3, immune checkpoints, markers of immune senescence, and phosphatidylinositol 3-kinase-Akt and NF-κB signaling intermediates in the former cohort and allowed the discovery of a 34-gene immune classifier prognostic for survival in independent validation series. Finally, 7 out of 15 patients (47%) with R/R AML and TP53 abnormalities showed complete responses to flotetuzumab (<5% BM blasts) on the CP-MGD006-01 clinical trial (NCT #02152956) and had significantly higher tumor inflammation signature, FOXP3, CD8, inflammatory chemokine, and PD1 gene expression scores at baseline compared with nonresponders. Patients with TP53 abnormalities who achieved a complete response experienced prolonged survival (median, 10.3 months; range, 3.3-21.3 months). These results encourage further study of flotetuzumab immunotherapy in patients with TP53-mutated AML.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/bloodadvances.2020002512

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Cited by

See all 154

Metadata

Authors
Vadakekolathu, J., Lai, C., Reeder, S., Church, S. E., Hood, T., Lourdusamy, A., Rettig, M. P., Aldoss, I., Advani, A. S., Godwin, J., Wieduwilt, M. J., Arellano, M., Muth, J., Yau, T. O., Ravandi, F., Sweet, K., Altmann, H., Foulds, G. A., Stölzel, F., Middeke, J. M., Ciciarello, M., Curti, A., Valk, P. J. M., Löwenberg, B., Gojo, I., Bornhäuser, M., DiPersio, J. F., Davidson-Moncada, J. K., & Rutella, S.
Venue
Blood Advances
Published
2020-10-15
Volume
4
Issue
20
Pages
5011-5024
ISSN
  • 2473-9529 (ISSN-L)
  • 2473-9537
OpenAlex
W3093280293
Cited by
154
References
21
FWCI
12.15
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML. https://app.cochat.ai/papers/10.1182/bloodadvances.2020002512
The paper
Vadakekolathu, J., Lai, C., Reeder, S., Church, S. E., Hood, T., Lourdusamy, A., Rettig, M. P., Aldoss, I., Advani, A. S., Godwin, J., Wieduwilt, M. J., Arellano, M., Muth, J., Yau, T. O., Ravandi, F., Sweet, K., Altmann, H., Foulds, G. A., Stölzel, F., . . . Rutella, S. (2020). TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML. Blood Advances. https://doi.org/10.1182/bloodadvances.2020002512

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.